Trehan Anupam, Anand Rachna, Kumari Puja, Singh Harinder, Soni Neha, Madan Ravij, Matta Raman, Maheshwari Sameer, Verma Manoj K
Strategy and Design, Bright Lifecare Pvt Ltd, Gurugram, IND.
Scientific Research, Bright Lifecare Pvt Ltd, Gurugram, IND.
Cureus. 2025 Apr 1;17(4):e81555. doi: 10.7759/cureus.81555. eCollection 2025 Apr.
Background Creatine monohydrate is a widely utilized dietary supplement in sports nutrition, valued for its role in enhancing muscle energy availability, power output, and performance during high-intensity, short-duration activities. Creatine monohydrate is effective but limited by absorption inefficiencies and side effects. Enhanced forms can improve uptake, reduce gastrointestinal discomfort, and optimize muscle energy utilization, meeting athletes' evolving performance needs. Methods This study involved 32 healthy male volunteers aged 18-50 years, with a BMI of 18.5-25.0 kg/m² and body weight of ≥50 kg. This study evaluated the bioavailability and safety of MuscleBlaze Creatine Monohydrate (CreAMP™) (Bright Lifecare Pvt Ltd, Gurugram, India), containing 3.0 g creatine monohydrate and 0.1 g Creabsorb™ (Indian Patent: IN202311057466), against a standard 3.0 g micronized creatine dose. In a double-blind, randomized crossover trial (CTRI/2024/08/073021), 32 healthy males (18-50 years) received both formulations under fasting conditions. The study compared two oral creatine monohydrate formulations: CreAMP™ Micronized Creatine Monohydrate (test) and Regular Micronized Creatine Monohydrate (reference) (Bright Lifecare Pvt Ltd, Gurugram, India). Blood samples were collected pre-dose and up to six hours post-dose over two periods, separated by a washout period of one week. Pharmacokinetic parameters were analyzed using Phoenix® WinNonlin® 8.5 (Certara, Radnor, PA). Results CreAMP™ has significantly higher bioavailability, absorption, and plasma retention compared to the reference formulation. With a 38.97% increase in bioavailability, an 18.10% higher C, a 21.37% longer half-life, 34.67% lower clearance, and a 10.13% higher mean residence time, CreAMP™ demonstrates superior pharmacokinetic properties. These findings suggest that CreAMP™ offers improved creatine uptake, sustained plasma levels, and the potential for reduced dosing frequency, making it a more effective formulation for creatine supplementation. Conclusion The study findings establish CreAMP™ as a superior creatine formulation, offering enhanced bioavailability, faster absorption, and prolonged plasma retention. These pharmacokinetic advantages indicate that CreAMP™ offers more efficient creatine uptake, improved energy availability, and optimized performance support for athletes.
一水肌酸是运动营养领域广泛使用的膳食补充剂，因其在高强度、短时间活动中增强肌肉能量供应、提高功率输出和表现方面的作用而受到重视。一水肌酸效果显著，但受吸收效率低和副作用的限制。强化形式可以提高吸收率、减少胃肠道不适并优化肌肉能量利用，满足运动员不断变化的表现需求。方法：本研究纳入了32名年龄在18至50岁之间、体重指数（BMI）为18.5至25.0kg/m²且体重≥50kg的健康男性志愿者。本研究评估了含有3.0g一水肌酸和0.1g Creabsorb™（印度专利：IN202311057466）的MuscleBlaze一水肌酸（CreAMP™）（印度古尔冈Bright Lifecare Pvt Ltd公司）相对于标准3.0g微粉化肌酸剂量的生物利用度和安全性。在一项双盲、随机交叉试验（CTRI/2024/08/073021）中，32名健康男性（18至50岁）在禁食条件下接受了两种制剂。该研究比较了两种口服一水肌酸制剂：CreAMP™微粉化一水肌酸（试验组）和普通微粉化一水肌酸（对照组）（印度古尔冈Bright Lifecare Pvt Ltd公司）。在两个时间段内，给药前和给药后长达6小时采集血样，两个时间段之间间隔一周的洗脱期。使用Phoenix® WinNonlin® 8.5（美国宾夕法尼亚州拉德诺Certara公司）分析药代动力学参数。结果：与对照制剂相比，CreAMP™具有显著更高的生物利用度、吸收率和血浆保留率。CreAMP™的生物利用度提高了38.97%，血药浓度（C）高18.10%，半衰期长21.37%，清除率低34.67%，平均驻留时间长10.13%，显示出优越的药代动力学特性。这些发现表明，CreAMP™能改善肌酸吸收、维持血浆水平，并有可能降低给药频率，使其成为更有效的肌酸补充制剂。结论：研究结果确立了CreAMP™作为一种优越的肌酸制剂，具有更高的生物利用度、更快的吸收和更长的血浆保留时间。这些药代动力学优势表明，CreAMP™能更有效地吸收肌酸，改善能量供应，并为运动员提供优化的表现支持。
